Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

New Roche compounds inhibit amidolytic activity of factor VIIa/tissue factor complex

Aug. 1, 2000

TxA2 antagonism and antiplatelet effects of new torasemide derivative BM-531

July 28, 2000

Rapid thrombolysis without reocclusion following acute bolus administration of novel modified t-PA

July 24, 2000

AstraZeneca describes new P2T receptor antagonists useful as antithrombotics

July 21, 2000

Innohep approved by FDA for DVT

July 20, 2000

FDA clears ConjuChem to initiate phase I/II trial of thrombin inhibitor

July 18, 2000

Berlex presents newly synthesized series of anticoagulants

July 17, 2000

Biopure reaches enrollment milestone in pivotal phase III trial of Hemopure

July 17, 2000

Novo Nordisk presents new heterocyclic inhibitors of factor VIIa-TF activity

July 12, 2000

Anticoagulant 2-pyridones under study at Sanofi-Synthelabo

July 10, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...